Sign In
Buy PCRX
$25.54
+0.0600 (+0.235%)
At Close: Jul 13, 2026
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:00am, Wednesday, 08'th Jul 2026
BRISBANE, Calif., July 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of pati
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal
10:30am, Wednesday, 01'st Jul 2026
PCRX is set to sell its iovera franchise to ZBH in a deal worth up to $140M as it sharpens focus on biopharmaceutical growth.
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL®
08:00am, Wednesday, 01'st Jul 2026
-- Expands Patient Access to Non-Opioid Postsurgical Pain Management Across Outpatient Settings -- BRISBANE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet
07:30am, Tuesday, 30'th Jun 2026
-- Pacira to receive up to $140 million with $70 million upfront and up to an additional $70 million in potential future revenue-based milestone payments -- -- Two companies will collaborate on advanc
Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting
05:53pm, Tuesday, 09'th Jun 2026
BRISBANE, Calif., June 9, 2026 /PRNewswire/ -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain thera
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
03:28pm, Monday, 08'th Jun 2026
Pacira BioSciences, Inc. (PCRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Election of Even a Single DOMA Nominee Would Risk Compromising Pacira's Strong Forward Momentum Leading Independent Experts ISS, Glass Lewis and Egan-Jones Agree that DOMA Representation Is Not Warran
ISS Concludes "There is a Compelling Reason to Support all Management Nominees" and Notes "the Dissident Has Not Presented a Compelling Case for Change" BRISBANE, Calif., June 1, 2026 /PRNewswire/ --
PharmaCorp Rx Inc. Announces First Quarter 2026 Financial Results
09:00am, Monday, 01'st Jun 2026
First quarter 2026 revenue up 79.4% compared to the first quarter of 2025 First quarter 2026 gross profit increased 71.9% compared to the first quarter of 2025 First quarter same-store sales were up 7
Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira's Director Nominees
04:20pm, Thursday, 28'th May 2026
BRISBANE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the “Company” or “Pacira”), the industry leader in its commitment to deliver innovative, non-opioid
PACIRA'S STOCK PRICE IS DOWN FOR EVERY RECENT PERIOD: 10 YEAR, 5 YEAR, 3 YEAR, 2 YEAR, ONE YEAR, AND YEAR-TO-DATE DOMA BELIEVES MANAGEMENT IS MISLEADING STAKEHOLDERS REGARDING ITS PATENT PROTECTION AN
Pacira BioSciences Mails Letter to Stockholders Reiterating Confidence in the Company's Strategic Direction and Highly Qualified Nominees
04:20pm, Wednesday, 27'th May 2026
Clarifies DOMA's Inaccuracies and the Reality of Pacira' Efforts to Strengthen its Market Position Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BL
Findings presented at ISPOR 2026 showed lower opioid consumption, reduced healthcare costs, and fewer opioid-related adverse events associated with EXPAREL use BRISBANE, Calif., May 27, 2026 (GLOBE NE
Pacira BioSciences Sets the Record Straight Regarding DOMA's Misleading Statements About Pacira's Intellectual Property Strategy
08:00am, Tuesday, 26'th May 2026
Urges Stockholders to Vote “ FOR ” the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (
PharmaCorp Announces Definitive Agreement to Acquire PharmaChoice Canada Bannered Pharmacy in Ontario
09:27am, Monday, 25'th May 2026
Purchase price of approximately $8.2 million The acquisition represents a continued expansion of PharmaCorp's footprint in Ontario SASKATOON, Saskatchewan, May 25, 2026 (GLOBE NEWSWIRE) -- PHARMACORP
